While consumer genomics grabs headlines, GeneDx (sema4.com) has quietly built the #1 genomic test preferred by 80% of genetic and pediatric providers. This is precision medicine at scale, and it's changing how diagnoses happen.

"In genetic testing, speed isn't just a feature—it's the difference between a family living in uncertainty or having answers."

The domain sema4.com redirects to geneDx.com, but the product focus is crystal clear: delivering precise, fast, and actionable diagnoses. Their tech stack (jQuery, Tailwind, GSAP) suggests a pragmatic, functional approach—medical software that works, not flashy demos. The absence of public traffic data isn't a weakness; it's a signal of a B2B enterprise model where sales cycles are long and relationships are direct.

• Dominant B2B position: 80% provider preference creates a powerful network effect
• High-value diagnostics: $218M revenue with 365 employees indicates premium pricing
• Capital efficiency: $791M funding suggests heavy R&D and regulatory investment
• Enterprise focus: No public traffic because they sell through institutions, not direct-to-consumer
• Full-stack clinical integration: From sample to diagnosis with actionable results